The pleiotropic cytokine interleukin-6 (IL-6) contributes to malignant progression and apoptosis resistance of various cancer types. Although IL-6 is elevated in malignant gliomas, and glioma cells respond to IL-6, its functional role in gliomagenesis is unclear. We have investigated this role of IL-6 in a mouse model of spontaneous astrocytoma by crossbreeding glial fibrillary acidic protein (GFAP)-viral src oncogene transgenic mice with IL-6-deficient mice. We show here that ablation of IL-6 prevents tumour formation in these predisposed animals, but did not affect preneoplastic astrogliosis. Moreover, we demonstrate phosphorylation and nuclear translocation of the transcription factor signal transducer and activator of transcription (STAT)3, a prerequisite for IL-6 signalling, in 51 human gliomas WHO grade II-IV and all experimental mouse tumours investigated. Together with the observation that STAT3 activation increases with malignancy, these findings indicate an important role for IL-6 in the development and malignant progression of astrocytomas.
Introduction
Gliomas are the most common primary brain tumours in humans. They fall into four grades, of which grade IV, glioblastoma multiforme (GBM), is the most aggressive and the most frequent one (Kleihues and Cavenee, 2000) . Owing to their diffuse infiltrative nature most gliomas are not curable by surgery alone, and their obstinacy to radio-and chemotherapy makes them extraordinarily lethal with a median survival of less than 1 year for GBM patients (Maher et al., 2001) . Treatment modalities did not change markedly for decades and are based on a sketchy conception of the mechanisms that drive gliomagenesis. Insights from animal models are just starting to unravel the genetic routes and the biological behaviour of gliomas (Holland, 2001) .
Several reports have suggested a possible role for the cytokine interleukin-6 (IL-6) in the pathogenesis of astrocytic tumours. IL-6 is mitogenic for astrocytes (Selmaj et al., 1990) , and, together with its soluble receptor (sIL-6Ra), induces a massive reactive gliosis in IL-6/sIL-6Ra double-transgenic mice (Brunello et al., 2000) . CNS-specific expression of IL-6 causes lifelong gliosis in transgenic mice (Campbell et al., 1993) . IL-6 is expressed by human glioblastoma cell lines (Van Meir et al., 1990) , and patients with malignant gliomas exhibit increased IL-6 levels that correlate with the histopathological grade of the neoplasm . Upregulation in astrocytomas might be caused by the amplification of the IL-6 gene (Tchirkov et al., 2001 ). IL-6 can promote glial tumour cell growth by an auto/ paracrine mechanism (Goswami et al., 1998) .
IL-6 imparts its signal into the cell by forming a complex with IL-6Ra and gp130, a transmembrane glycoprotein, and phosphorylation of signal transducer and activator of transcription (STATs) by gp130-associated janus kinases (JAKs) (Heinrich et al., 1998; Hirano et al., 2000) . STAT proteins are latent cytoplasmic transcription factors that are transiently recruited to activated cytokine receptors through their SH2 domains. After IL-6 stimulation, STAT3 and STAT1 become phosphorylated, dimerize and translocate to the nucleus where they rapidly bind to DNA and trigger transcription of target genes. Normally, activation of STAT3 is rapid and transient and absent in astrocytes of unlesioned brain (Justicia et al., 2000) . Mutation of tyrosine-705 to phenylalanine (Y705F) inhibits IL-6-induced tyrosine phosphorylation of STAT3 (Kaptein et al., 1996) . A constitutively active form of STAT3 (STAT3-C) that can dimerize in the absence of tyrosine phosphorylation is sufficient to induce cellular transformation of fibroblasts and tumour growth in nude mice (Bromberg et al., 1999) . These findings suggest that IL-6 may promote tumour development by activating STAT3.
The central aim of our study was to examine the functional role of IL-6 in gliomagenesis. To this end, we made use of our transgenic mouse model of astrocytoma that expresses the viral src oncogene (v-src) in the context of a full-length murine glial fibrillary acidic protein (GFAP) transgene (Weissenberger et al., 1997) . GFAP-v-src þ /À mice being wild type at the IL-6 gene locus develop spontaneous astrocytomas and peripheral nerve tumours in a multistage tumourigenesis process involving progression from low-to high-grade gliomas, diffuse single-cell infiltration and neovascular proliferation with a penetrance of around 20% (Weissenberger et al., 1997) . Tumours from v-src þ /À mice phenocopy human gliomas in terms of features like malignant progression, diffusely infiltrative tumour spread, necrosis bordered by pseudopalisading tumour cells and microvascular proliferation (Weissenberger et al., 1997; Theurillat et al., 1999) .
We have now extended our astrocytoma model by inactivating the IL-6 gene locus to better understand the biological role of IL-6 in the development of these tumours. Moreover, we have investigated by immunohistochemistry and Western blot analysis, whether STAT3, the relevant signal transducer of IL-6, is activated and translocated to the nucleus in human and in mouse tumours. We report here (i) that STAT3 is constitutively activated in human and murine gliomas, (ii) that the level of STAT3 activation increases with the histopathological grade, and (iii) that abrogation of IL-6 expression suppresses astrocytic tumour formation in GFAP-v-src transgenic mice.
Results

STAT3 is constitutively activated in human gliomas
Among all signalling pathways that are activated by IL-6, STAT3 is central in mediating cell growth, differentiation and survival signals (Heinrich et al., 1998; Hirano et al., 2000) . As a recent study has linked malignant glioma progression to increased levels of IL-6 , we examined whether persistent activation of STAT3 is present in human gliomas. We compared the STAT3 activation profile of 51 astrocytic tumours, including 27 GBMs (WHO grade IV), 14 anaplastic astrocytomas (WHO grade III) and 10 diffuse astrocytomas (WHO grade II), using specific antisera that recognize GFAP, STAT3a and pY-STAT3 (Figure 1a) . We found the expression of the latent form of STAT3 (STAT3a) in diverse cells of all human gliomas (Figure 1b ). Immunohistochemical analysis Figure 1 Constitutive STAT3 activation in human and mouse gliomas. (a) Cryostat sections of malignant human astrocytomas were stained with antibodies against GFAP, STAT3a and pY-STAT3. Tumour cells of an AA III showed strong GFAP immunoreactivity (red; left). STAT3a is abundantly expressed in astrocytoma cells (middle). pY-STAT3 shows nuclear localization in tumour cells (right). Magnification, Â 100. (b) Immunohistochemical analysis of STAT3a expression in human and mouse gliomas. Immunoreactivity scores were given in the following way: 0, zero, 1, o10%, 2, 10-50%, 3, 450% cells stained. In human tumours of all grades (i.e. Ast. II diffuse astrocytoma, Ast. III anaplastic astrocytoma, GBM IV glioblastoma multiforme) STAT3a was found in tumour cells (Tu), reactive astrocytes (RA), endothelial cells (EC) and smooth muscle cells (SM). In mouse tumours STAT3a was allotted to tumour cells (Tu), reactive astrocytes (RA) and smooth muscle cells (SM) in all grades. (c) pY-STAT3 activation levels in human and mouse gliomas. In human gliomas pY-STAT3 was markedly elevated in tumour cells (Tu) as well as in endothelial cells (EC) and increased with the histopathological grade. Similarly, in mouse gliomas pY-STAT3 was elevated in tumour cells (Tu) and correlated with malignancy, but was absent in endothelial cells localized the STAT3a protein in human astrocytomas to neoplastic cells, to reactive astrocytes, and endothelial cells of blood vessels within the tumour. A different pattern emerged for the activated, tyrosine-705-phosphorylated form of STAT3 (pY-STAT3). Activated STAT3 was allotted to tumour cells and endothelial cells in human WHO grade II-IV tumours (Figure 1c) . In these two cell populations, the level of activation, that is, phosphorylation of tyrosine-705, appeared to increase gradually with the WHO grade (Figure 1c) . Therefore, STAT3 activation may represent a prognostic molecular marker in gliomas.
STAT3 activation levels correlate with the histopathological grade
To provide further independent confirmation that the aggressiveness of human gliomas is linked to IL-6 signalling Tchirkov et al., 2001) , in which STAT3 activation is a critical step (Zhong et al., 1994) , we directly measured the amounts of pY-STAT3 in 15 human gliomas, five diffuse astrocytomas (WHO grade II), five anaplastic astrocytomas (WHO grade III), five GBMs (WHO grade IV) and -as control -in unlesioned human brain by Western blot analysis and normalized them to total STAT3a protein. Using the same STAT3a and pY-STAT3 antibodies, we could confirm the results of our immunohistochemical study. Unlike in normal brain, STAT3a was highly upregulated in all tumours investigated (Figure 2b ). pY-STAT3 was absent in unlesioned brain (Figure 2b) . However, the level of tyrosine-705 phosphorylation increased with malignancy being highest in GBM (Figure 2a) , the tumour entity with the poorest prognosis.
Interestingly, in low-grade human gliomas pY-STAT3 was always located in the nucleus (Figure 4a ). Yet, in high-grade human gliomas, for example, GBM, we found in addition to the nuclear localization of activated STAT3 a distinct plasma membrane-associated immunoreactivity for pY-STAT3 (Figure 4b ). This specific pY-STAT3 staining at the plasma membrane was preferentially found in neoplastic cells at the margin of necrosis (Figure 4b ).
STAT3 is constitutively activated in mouse gliomas
To examine whether STAT3 is constitutively activated in our murine gliomas, the expression of STAT3a and pY-STAT3 was assessed by immunohistochemistry of paraffin-embedded sections of tumours that originated spontaneously in heterozygous GFAP-v-src mice (vsrc þ /À ). In the brains of wild-type (BL/6) and IL-6 knockout mice (IL-6 À/À ), we could not detect expression nor activation of STAT3 in astrocytes (Figure 3b , c, e and f). STAT3 expression and activation was found in few neurons of the cerebral cortex and the brain stem (not shown). In the brains of v-src þ /À transgenic mice, we found STAT3a abundantly expressed in dysplastic astrocytes and pY-STAT3 was translocated to the nuclei (Figure 3h Tumour phenotype is indicated as Ast. II, diffuse astrocytoma; Ast. III, anaplastic astrocytoma; GBM, glioblastoma multiforme. Brain lysates containing 100 mg of protein were resolved in a 8% SDS-PAGE, blotted, probed for pY-STAT3 and reprobed for STAT3a levels. (a) Relative STAT3 activation levels were quantified by scanning densitometry and normalized to STAT3a. (b) Consistent with our immunohistochemical data, STAT3a is strongly upregulated in all tumour grades. Active STAT3 is absent in normal adult brain, whereas tyrosine-705 phosphorylation increases with the degree of malignancy IL-6 in gliomagenesis J Weissenberger et al staining of pY-STAT3 (Figures 3n and 4d) . Here, the plasma membrane localization of active STAT3 was most prominent at the tumour margin (Figures 3n and  4d ). This distinct plasma membrane localization might represent the preassociation of cytokine-activated pY-STAT3 with raft proteins (Sehgal et al., 2002) .
Mouse gliomas harbour activated microglia
In cultures, microglial cells were shown to produce proinflammatory cytokines and chemokines upon various types of challenges (Kreutzberg, 1996) . To find out whether microglial cells were activated in spontaneous 
Abrogation of IL-6 prevents glial tumour formation in GFAP-v-src mice
To assess the functional role of IL-6 in gliomagenesis, we compared the tumour incidence in heterozygous GFAP-v-src transgenic mice that express IL-6 (v-src þ /À ) with heterozygous GFAP-v-src transgenic mice that lack IL-6 (v-src
) and with IL-6 knockout mice (IL-6 À/À ) as control (Kopf et al., 1994) . Astrocytes of IL-6 À/À mice looked morphologically normal (Figure 3a-f ). In contrast, dysplastic GFAP-immunoreactive astrocytes of v-src þ /À transgenic mice showed nuclear pleomorphism and coarse processes (Figure 3g and j) . Interestingly, the lack of IL-6 appeared not to affect GFAP expression and cell morphology of dysplastic astrocytes in the brains of v-src þ /À /IL-6 À/À mice (Figure 3j ), suggesting that factors other than IL-6 are involved in this type of astrogliosis. Although all tumours showed intense cytoplasmic GFAP immunoreactivity with typical glial processes (Figure 3m-o) , no inflammatory mononuclear cells were found in or around the tumours. As expected, all IL-6 À/À mice (0/ 32) remained tumour-free over the entire observation period of 65 weeks ( Figure 5 ). In all, 21% of the v-src À/À animals (2.8%) developed a neoplasm (Figures 3o and 5) . These experiments show that IL-6 promotes glioma development in vivo, and its loss results in the suppression of Trangene expression is maintained in
It has been shown that the GFAP promoter can be activated via STAT3 by an IL-6-sILR6 fusion protein (Takizawa et al., 2001) . To rule out that the reduced tumour incidence rate in v-src (Figure 3g and j) . Therefore, another mechanism must be operative to prevent tumour formation in IL-6-deficient v-src þ /À mice.
Discussion
As IL-6 is considered to promote glial tumour cell growth (Candi et al., 1997; Goswami et al., 1998), we hypothesized that inactivation of IL-6 might directly influence tumour formation. This was indeed the case. While GFAP-v-src transgenic mice being wild type at the IL-6 locus developed spontaneous astrocytomas with a penetrance of 21%, abrogation of IL-6 led to an almost complete suppression of tumour formation in these predisposed animals.
How exactly IL-6 contributes to gliomagenesis is not clear. Under normal conditions, IL-6-mediated STAT3 activation is transient and continuous stimulation does not lead to permanent STAT3 activation (Fischer et al., 2003) . Inactivation of IL-6-induced feedback inhibitors like SOCS1 and SOCS3 by hypermethylation might come into play. For example, SOCS3 was found to be frequently silenced in human lung cancer by promoter methylation, and reciprocally, ectopic expression of SOCS3 induced growth suppression in NSCLC cells (He et al., 2003) . One interesting point is the finding that in GBM cells STAT3 activation was in part caused by autocrine IL-6 (Rahaman et al., 2002) , and that neutralizing IL-6 antibodies reduced STAT3 activation by 70% (Rahaman et al., 2002) . This reduction in turn inhibited proliferation and induced apoptosis by downregulating antiapoptotic proteins of the Bcl-2-family (Rahaman et al., 2002) . Shirogane et al. (1999) demonstrated that the protooncogene Pim-1 is a downstream target of STAT3 and cooperates with c-myc to promote cell proliferation and antiapoptosis in haematopoietic cells. Consistent with this, IL-6 showed antiapoptotic (Leu et al., 2003) . On the other hand, a recent study showed that VEGF expression correlates with constitutive STAT3 activity in diverse cancer cell lines and that VEGF is regulated directly by activated STAT3 (Niu et al., 2002) . Much more intriguing, for human cervical cancer it was demonstrated that IL-6 promotes tumour angiogenesis by activating VEGF via STAT3 (Wei et al., 2003) . Therefore, IL-6 might promote tumour growth by facilitating neoangiogenesis. IL-6 is also capable of inducing the expression and secretion of matrix metalloproteinases like MMP-2 and MMP-9 in normal and tumour cells (Kossakowska et al., 1999) . In postmortem glioblastoma specimens, IL-6, MMP-2, MT-MMP and VEGF were found to be strongly expressed in reactive glial cells around the tumour (Nagashima et al., 2002) . Thus, IL-6 may contribute to the invasion of glioma cells through the induction of matrix degrading proteinases.
To our surprise, the absence of IL-6 did not affect the preneoplastic astrogliosis in GFAP-v-src mice. We showed previously that overexpression of IL-6 in transgenic mice leads to a severe reactive gliosis (Brunello et al., 2000) , and others demonstrated that the absence of IL-6 impairs reactive astroglial transformation (Klein et al., 1997) . However, this effect appears to be dependent on the type of lesion, as MPTP-induced astrogliosis is not impaired in mice lacking IL-6 (Cardenas and Bolin, 2003) . Since IL-6 has been shown to regulate astrogliosis by autocrine and paracrine mechanisms (Van Wagoner et al., 1999) , other factors must have induced the observed astrogliosis in v-src
À/À mice. In this context, it is interesting to note that activated microglial cells were absent from the foci of preneoplastic gliosis in v-src þ /À mice, but frequent in vsrc þ /À gliomas. In addition, lymphocytic infiltration did not occur in our model. These results suggest that inflammatory mechanisms are not involved in the development of preneoplastic gliosis in v-src þ /À mice. Since constitutive STAT3 signalling is involved in oncogenic gene activation (Buettner et al., 2002) , it is not surprising that we found strong overexpression and STAT3 activation in both human and mouse gliomas by Western blot and immunohistochemistry analysis. Moreover, the level of STAT3 activation increased with the grade of malignancy. Similar findings were reported by other groups that have investigated STAT3 activation in human gliomas (Schaefer et al., 2002) and astrocytoma cell lines (Konnikova et al., 2003) . In addition, knockdown of STAT3 expression by RNAi induced apoptosis in astrocytoma cells but not in primary astrocytes, suggesting that STAT3 is required for the survival of these tumours (Konnikova et al., 2003) .
In low-grade gliomas of both human and mouse, we saw in all cases a nuclear translocation of pY-STAT3 in dysplastic and neoplastic astrocytes. This is in line with the common concept that pY-STAT3 homodimers enter the nucleus where they regulate gene expression (Hirano et al., 2000) . Yet, in high-grade gliomas of both human and mouse tumours, we observed, in addition to the expected nuclear localization, a novel distinct plasma membrane-associated immunoreactivity for pY-STAT3. This observation is compatible with recent findings, suggesting that STAT proteins do not float solely as free monomers in the cytosol of mammalian cells but constitute high molecular mass protein complexes in lipid rafts (Sehgal et al., 2002) and/or dimerize prior to its activation (Kretzschmar et al., 2003) . Raft proteins reside in specialized microdomains at the cell surface and are thought to play an important role in receptor signalling. Intriguingly, treatment of cells with the raftbreaking compound methyl-b-cyclodextrin markedly inhibited IL-6-induced signalling (Sehgal et al., 2002) . Recently, STAT3 dimerization and subcellular localization was studied in living cells (Kretzschmar et al., 2003) . Live cell imaging (FRET) demonstrated that fusion proteins with spectral variants of green fluorescent protein, CFP and YFP redistributed -like wildtype STAT3 -from a preferentially cytoplasmic to a nuclear localization upon IL-6 stimulation. Normalizing FRETc/YFP signals revealed a gradient from the plasma membrane to the cell interior demonstrating a steady state of STAT3 activation at the plasma membrane and inactivation in the nucleus (Kretzschmar et al., 2003) . Thus, the plasma membrane-associated immunoreactivity of pY-STAT3 seen in our gliomas in all likelihood resembles an acute signalling state of a stimulated cell.
The impaired tumour growth in v-src þ /À /IL-6 À/À mice cannot be explained by a shut down of GFAP-v-src transgene expression in the absence of IL-6. Our RT-PCR and immunohistochemical results defy such an explanation. Transgene expression was maintained over the entire observation period of 60 weeks. In addition, the unaltered astrogliosis phenotype in v-src þ /À /IL-6 À/À animals speaks against the downregulation of the transgene. A plausible model explaining as to how abrogation of IL-6 could lead to the suppression of tumour formation was put forward in a recent paper where Rac1, a small GTP-binding protein, was shown to mediate STAT3 activation by autocrine IL-6 (Faruqi et al., 2001) . Intriguingly, the suppression of Rac1 induces apoptosis in several human glioma cell lines regardless of p53, MDM2 or EGFR mutational status, but not in normal human astrocytes (Senger et al., 2002) . To start the autocrine signalling loop, Faruqi et al. (2001) propose an 'inside-out' rather than an 'outside-in' signalling model initiated by Rac1-induced NF-kB activation that leads to IL-6 gene expression. In their model, the secreted IL-6 then binds to its receptor and activates the JAK/STAT pathway. Tyrosine-phosphorylated STAT3 proteins dimerize, translocate to the nucleus and bind to DNA target sites of responsive genes inducing a genetic programme of oncogenic transformation. The fact that this loop was blockable by neutralizing IL-6 receptor antibodies or by a mutant form of I-kB supports their hypothesis. Rac1 is activated by hypoxia and required for HIF-1a expression and transcriptional activity (Hirota and Semenza, 2001 ), a condition commonly found in GBM. In addition, human malignant astrocytoma cells and high-grade astrocytoma tissue show aberrant NF-kB activity, which promotes their growth (Nagai et al., 2002) . Therefore, one is tempted to speculate that inactivation of IL-6 in our v-src þ /À /IL-6 À/À mice foiled the establishment of an autocrine IL-6 activation loop leading to impaired tumour formation.
Materials and methods
Mice
The generation of GFAP-v-src and IL-6 À/À mice has been described previously (Kopf et al., 1994; Weissenberger et al., 1997) . All three transgenic lines have been put on a C57Bl/6 background by backcrossing over more than seven generations. IL-6 À/À females were crossbred with GFAP-v-src 
mice were crossbred with C57Bl/6 mice. Heterozygous GFAP-v-src þ /À mice were mated with C57Bl/6 mice to expand the v-src þ /À population. Mice were monitored over 65 weeks or until they showed neurological symptoms related to brain tumours, at which time point they were killed and subjected to autopsy, including regenotyping. Histological characterizations included comparisons of littermates. Animal care and use followed the institutional guidelines and was approved by the authorities of the Kanton Bern.
Histopathological analysis
Mice were euthanized using CO 2 gas. Brains were removed and fixed in PBS/4% paraformaldehyde over night at room temperature, and then embedded in paraffin. Haematoxylin and eosin (H&E) stainings were performed according to standard procedures. For immunohistochemistry, 2-3 mm paraffin sections were stained with a monoclonal antibody against GFAP (clone 6F2; 1 : 50 dilution; DakoCytomation, Glostrup, Denmark) or against avian Src (v-src; clone E10; 1 : 100 dilution; Upstate, Lake Placid, NY, USA) as described below. Cryostat and paraffin sections from human gliomas (WHO grade II-IV) and paraffin sections from mouse tissues were probed with polyclonal antibodies against STAT3a (1 : 400 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or tyrosine-705-phosphorylated pY-STAT3 (1 : 200 dilution; Cell Signaling Technology, Beverly, MA, USA). In the negative control sections, the primary antibody was replaced with dilution buffer. Prior to staining, sections were dewaxed, rehydrated and pretreated by boiling in a microwave oven either in 10 mM citrate buffer, pH 6.0 (GFAP) or in 100 mM Tris-5% urea (pY-STAT3), pH 9.0, or by boiling in a pressure cooker (STAT3a; citrate buffer). Sections were then (and following all subsequent steps) washed in Tris-buffered saline (TBS) and incubated with the primary antibody diluted in TBS with 0.5 % casein and 5% normal goat serum (dilution buffer), for 60 min at room temperature. Next, a 1 : 300 dilution (same buffer as primary antibody) of a biotinylated goat-anti-mouse immunoglobulin (Ig) or a 1 : 500 dilution of a goat-anti-rabbit Ig antiserum (DakoCytomation) was applied for 45 min. Thereafter, sections were incubated with a streptavidin-biotin complex/alkaline phosphatase (StrABC/ AP; 1 : 200 in TBS) (DakoCytomation) for 45 min. Finally, sections were developed in new fuchsin-naphtol AS-BI (Sigma, St Louis, MO, USA), counterstained with haematoxylin and mounted. To demonstrate microglia, deparaffinized sections from mouse brains were incubated with biotinylated isolectin from Bandeiraea simplicifolia BSI-B 4 (Sigma) (concentration: 50 mg/ml in dilution buffer), which was visualized using the same StrABC/AP technique as above. In the negative control sections, BSI-B 4 was replaced with dilution buffer.
Western blot analysis
Human tumour biopsy samples were frozen in liquid nitrogen immediately upon removal from the patient. Mouse brains and tumours were snap-frozen in liquid nitrogen and weighed. Tissue (10% weight/volume) was homogenized in ice-cold buffer containing 0.32 M sucrose, 0.5% NP-40, 0.5% sodium deoxycholate plus 1 mM NaVO 4 and Complete s protease inhibitor cocktail (Roche Diagnostics, Rotkreuz, Switzerland). Lysates were cleared by centrifugation and 100 mg of each sample was resolved by 8% SDS-PAGE. Proteins were transferred to nitrocellulose by semidry blotting. Membranes were blocked with PBS/5% nonfat milk, incubated with a polyclonal antibody against STAT3a (1 : 1000 dilution; Santa Cruz Biotechnology) or against pY-STAT3 (Tyr705) (1 : 1000 dilution; Cell Signaling Technology) in PBS with 0.1% Tween-20 and 2.5% nonfat milk. Bound antibody was visualized using the ECL chemoluminescence detection system (Amersham Pharmacia Biotech Europe, Du¨bendorf, Switzerland) following the manufacturer's guidelines.
RT-PCR
Total RNA was isolated from snap-frozen mouse brains with the Qiagen RNeasy Kit (Qiagen AG, Basel, Switzerland). A measure of 1 mg was reverse transcribed using the GeneAmp RNA PCR Kit (Applera Europe, Rotkreuz, Switzerland). One-fourth of the resulting complementary DNA was subjected to 30 cycles of PCR amplification using transgenespecific primers in 1 Â PCR buffer (Promega, Madison, WI, USA) containing 1.25 mM MgCl 2 . For internal control we used b-actin. The amplified products (predicted sizes 415 bp for vsrc, 592 bp for GFAP and 535 bp for b-actin) were resolved on 2% agarose gels. Primer sequences and details of PCR conditions are available upon request.
